Company intelligence / Profile preview

BioMolecular Products, Inc.

Bradford, Massachusetts, United Statesbiomolecularproductsinc.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company’s Lym-X-Sorb® technology has demonstrated improved choline status in children with cystic fibrosis in a randomized controlled trial, and enabled complete responses in four out of eighteen neuroblastoma patients at high dosing levels with an oral powder formulation of fenretinide. The technology improves solubilization, stability, and bioavailability of poorly soluble drugs[6].

Therapeutic areas: OncologyRare DiseasesOther
Modalities: Lipid-based drug delivery systems (notably Lym-X-Sorb®)Small molecules (as compatible payloads)
Industry: Biotech

Drug pipeline

2 assets

Fenretinide Lym-X-Sorb

Unknown

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on BioMolecular Products, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioMolecular Products, Inc..

Explore the full profile